Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126438391 | 12643839 | 1 | I | 20160621 | 20160729 | 20160811 | 20160811 | EXP | GB-MHRA-MIDB-8F262AB7-7348-48B6-9982-BD12C81FE9A8 | GB-TEVA-682639ACC | TEVA | 79.00 | YR | M | Y | 0.00000 | 20160811 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126438391 | 12643839 | 1 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | 15 MILLIGRAM DAILY; | Y | U | 77255 | 15 | MG | CAPSULE | QD | |||||
| 126438391 | 12643839 | 2 | C | ADCAL-D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | 0 | 1 | DF | CHEWABLE TABLET | |||||||||
| 126438391 | 12643839 | 3 | C | ALENDRONIC ACID | ALENDRONIC ACID | 1 | 0 | 70 | MG | TABLET | /wk | ||||||||
| 126438391 | 12643839 | 4 | C | ASPIRIN. | ASPIRIN | 1 | 75 MILLIGRAM DAILY; | 0 | 75 | MG | DISPERSIBLE TABLET | QD | |||||||
| 126438391 | 12643839 | 5 | C | ATORVASTATIN | ATORVASTATIN | 1 | 20 MILLIGRAM DAILY; AT NIGHT | 0 | 20 | MG | TABLET | QD | |||||||
| 126438391 | 12643839 | 6 | C | CARBOCISTEINE | CARBOCYSTEINE | 1 | 2250 MILLIGRAM DAILY; | 0 | 750 | MG | CAPSULE | TID | |||||||
| 126438391 | 12643839 | 7 | C | CYANOCOBALAMIN. | CYANOCOBALAMIN | 1 | 0 | 50 | UG | TABLET | |||||||||
| 126438391 | 12643839 | 8 | C | FLUCLOXACILLIN | FLUCLOXACILLIN | 1 | 2000 MILLIGRAM DAILY; | 24000 | MG | 0 | 500 | MG | CAPSULE | QID | |||||
| 126438391 | 12643839 | 9 | C | FOLIC ACID. | FOLIC ACID | 1 | 5 MILLIGRAM DAILY; | 0 | 5 | MG | TABLET | QD | |||||||
| 126438391 | 12643839 | 10 | C | RAMIPRIL. | RAMIPRIL | 1 | 2.5 MILLIGRAM DAILY; AT NIGHT | 32.5 | MG | 0 | 2.5 | MG | CAPSULE | QD | |||||
| 126438391 | 12643839 | 11 | C | RANITIDINE. | RANITIDINE | 1 | 150 MILLIGRAM DAILY; IN THE MORNING | 300 | MG | 0 | 150 | MG | TABLET | QD | |||||
| 126438391 | 12643839 | 12 | C | SALAMOL | ALBUTEROL | 1 | Respiratory (inhalation) | 400 MICROGRAM DAILY; | 0 | 100 | UG | QID | |||||||
| 126438391 | 12643839 | 13 | C | SALBUTAMOL | ALBUTEROL | 1 | 2.5MG/2.5ML NEBULISER LIQUID UNIT DOSE VIALS | 0 | |||||||||||
| 126438391 | 12643839 | 14 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | 2 DOSAGE FORMS DAILY; 400/12 | 0 | 1 | DF | BID | ||||||||
| 126438391 | 12643839 | 15 | C | TIOTROPIUM BROMIDE | TIOTROPIUM BROMIDE | 1 | Respiratory (inhalation) | 180 MICROGRAM DAILY; IN THE MORNING | 0 | 180 | UG | CAPSULE | QD | ||||||
| 126438391 | 12643839 | 16 | C | VERAPAMIL | VERAPAMIL HYDROCHLORIDE | 1 | 120 MILLIGRAM DAILY; | 1560 | MG | 0 | 120 | MG | TABLET | QD |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126438391 | 12643839 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126438391 | 12643839 | Dyspnoea | |
| 126438391 | 12643839 | Hyponatraemia | |
| 126438391 | 12643839 | Infective exacerbation of chronic obstructive airways disease | |
| 126438391 | 12643839 | Productive cough |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126438391 | 12643839 | 1 | 20160622 | 0 | ||
| 126438391 | 12643839 | 8 | 20160609 | 20160713 | 0 | |
| 126438391 | 12643839 | 10 | 20160608 | 0 | ||
| 126438391 | 12643839 | 11 | 20160623 | 0 | ||
| 126438391 | 12643839 | 16 | 20160608 | 0 |